Insight, China's Pharmaceutical Industry

Company Deals

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development

Advaccine Biotechnology (NEEQ: 874055) today disclosed a private placement offering of no more than 2,203,200 shares...

Company Drug

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC

Fineline Cube Oct 21, 2025

Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...

Company Deals

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108

Fineline Cube Oct 21, 2025

Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...

Company Drug

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors

Fineline Cube Oct 20, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...

Company Drug

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer

Fineline Cube Oct 20, 2025

CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...

Company Drug

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer

Fineline Cube Oct 20, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...

Company Drug

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC

Fineline Cube Oct 20, 2025

Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...

Company Drug

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion

Fineline Cube Oct 20, 2025

Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...

Company Deals

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Fineline Cube Oct 20, 2025

China Isotope & Radiation Corporation (HKG: 1763) announced today that it has signed a Memorandum...

Company Deals

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares

Fineline Cube Oct 20, 2025

Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...

Company Drug

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer

Fineline Cube Oct 20, 2025

Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...

Company Deals

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion

Fineline Cube Oct 20, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund...

Company Drug

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC

Fineline Cube Oct 20, 2025

Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...

Company Drug

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer

Fineline Cube Oct 20, 2025

Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...

Others

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

Fineline Cube Oct 20, 2025

Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...

Company Deals

Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros

Fineline Cube Oct 20, 2025

Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license...

Company Deals

Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers

Fineline Cube Oct 20, 2025

Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...

Company Deals

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies

Fineline Cube Oct 20, 2025

Shenzhen Pregene Biopharma Co., Ltd. has entered into a License and Collaboration Agreement with Kite,...

Company Deals

Aosaikang’s AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment

Fineline Cube Oct 17, 2025

Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced on October 17, 2025, that its subsidiary, AskGene...

Company Drug

Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer

Fineline Cube Oct 17, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...

Insight, China's Pharmaceutical Industry

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros

Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies

Aosaikang’s AskGene Pharma Licenses ASKG712 to Visara for Macular Disease Treatment

Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer

You Missed

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C